Wedbush Lowers Earnings Estimates for Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) – Research analysts at Wedbush reduced their FY2027 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a report released on Thursday, January 16th. Wedbush analyst Y. Zhong now forecasts that the biotechnology company will post earnings per share of $3.37 for the year, down from their prior estimate of $3.59. Wedbush currently has a “Outperform” rating and a $181.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.43) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s FY2028 earnings at $8.78 EPS.

A number of other research analysts also recently issued reports on ASND. TD Cowen cut their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Bank of America increased their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, Stifel Nicolaus raised their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $192.07.

Ascendis Pharma A/S Price Performance

ASND opened at $128.13 on Monday. The firm has a market capitalization of $7.78 billion, a PE ratio of -15.86 and a beta of 0.65. The business’s 50-day moving average is $133.13 and its two-hundred day moving average is $133.47. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. Signaturefd LLC lifted its stake in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the last quarter. Profund Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after buying an additional 85 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $30,000. Finally, GAMMA Investing LLC lifted its position in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.